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Background: Despite the widespread use of subcutaneous methotrexate in treating pediatric rheumatic disorders,
the amount of pain associated with the injections has not been quantified. Our study aims 1) to quantify the
amount of pain associated with subcutaneous injections of methotrexate, 2) to explore predictors of pain, 3) to
determine the frequency of patient-reported clinical adverse effects of methotrexate, and 4) identify coping
strategies of patients and caregivers.
Methods: Patients aged 4–17 years with rheumatologic diseases who were receiving weekly subcutaneous
methotrexate injections for at least 4 weeks were invited to participate in this prospective cohort study. They were
trained to use the Faces Pain Scale – Revised (FPS-R) and Faces, Legs, Arms, Cry, Consolability (FLACC) tools to rate
pain associated with the injections. All patients underwent focused interviews exploring their experiences with
methotrexate injections.
Results: Forty-one patients consented to the study. The mean age was 11.2 years (SD = 3.9 years) and 68% were
female. Most patients were diagnosed with JIA (73%). Mean duration of methotrexate therapy was 2.5 years
(SD = 2.1 yrs). All but one of the patients used methotrexate 25 mg/ml solution for injection in 1 cc or 3 cc syringe
with 30 gauge ½” needle. Median amount of pain was 2/10 on the FPS-R and 1/10 on the FLACC. Higher intensity
of pain was significantly associated with presence of side effects (p = 0.004), but not duration of therapy (p = 0.20)
or age (p = 0.24). Most participants (61%) experienced at least one adverse effect; nausea (56%) and vomiting (34%)
were the most common symptoms reported. Patients and caregivers reported using ice (34%), comfort positions
(51%), rewards (49%), reassurance (54%), distraction (51%), and analgesic medications (22%) to cope with the
injections.
Conclusion: Subcutaneous injections of methotrexate are associated with a mild amount of pain. Presence of side
effects may amplify the amount of perceived pain. Clinicians can apply this knowledge when counseling patients
and family members about methotrexate therapy.Background
Methotrexate has been an important component of treat-
ment for paediatric rheumatologic conditions for over
twenty years [1,2]. According to the German Pediatric
Rheumatology 1998 database, one in four patients diag-
nosed with chronic rheumatologic diseases received* Correspondence: rjurencak@cheo.on.ca
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unless otherwise stated.methotrexate treatment [3]. When prescribed to treat
these conditions, the recommended dose of methotrexate
is 0.3 to 1.0 mg/kg/week (maximal dose 25–30 mg/week)
via oral or subcutaneous routes. Weekly methotrexate
injections can be associated with increased anxiety in
patients with Juvenile Idiopathic Arthritis [JIA; 4], which
may be partly attributed to the injection pain and adverse
effects.
Procedural pain in paediatric populations is a concern
for clinicians due to its association with greater pain andl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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sensitivity, and long-term avoidance of medical treatment
[4,5]. For example, Weisman et al. [6] have shown that
children who do not receive proper pain control during
lumbar punctures and bone marrow aspiration report
higher amounts of pain for subsequent procedures, even
when adequate analgesia has been provided. Additionally,
some patients may develop needle phobia and experience
disproportionate amounts of fear or vasovagal syncope
when presented with needles [7].
Recognition of the negative consequences of inadequately
controlled paediatric pain has generated increased interest
in pain assessment and management for young patients [8].
A large portion of this research has focused on reducing
the pain of common paediatric procedures, such as routine
childhood immunizations, venipuncture, intramuscular in-
jections, and dressing changes [9,10]. To our knowledge,
there has not yet been a formal attempt to quantify and
reduce the amount of pain associated with subcutaneous
methotrexate injections in the paediatric rheumatology
population. These patients may be particularly vulnerable
to the long-term consequences of uncontrolled procedural
pain due to their young ages and relatively long duration
of therapy. A recent, large study of children with JIA re-
ceiving methotrexate from an average age of 6.1 years, for
a median duration of 29 months, found that methotrexate
had a detrimental impact on the patients' quality of life
[11]. Therefore, there is a need to improve the experience
of subcutaneous methotrexate administration. Measuring
the amount of pain associated with methotrexate provides
a baseline for determining the efficacy of interventions
and can aid clinicians in counseling patients and families
about to begin therapy.
Given the negative long-term effects of repeated exposure
to procedural pain and the vulnerability of the paediatric
rheumatology population using subcutaneous methotrex-
ate, our study aimed to address gaps in the existing litera-
ture by investigating the following objectives:
1) quantify the amount of pain associated with
subcutaneous methotrexate injections,
2) investigate the factors that influence the amount
of perceived pain and identify effective pain
management strategies used by patients and
families, and
3) determine the frequency of clinical adverse
effects of subcutaneous methotrexate and
effective treatments as reported by the patients
and families, and
4) identify coping strategies of patients and caregivers.
Methods
Study design
Observational prospective cohort study.Study population
All patients at the Children's Hospital of Eastern Ontario
Rheumatology Clinic with appointments scheduled be-
tween June and August 2013 were screened for their eligi-
bility to participate in this study.
Inclusion and exclusion criteria
Patients were invited to participate in the study if they
were between the ages of 4 and 17 and were currently
receiving subcutaneous injections of methotrexate for at
least 4 weeks.
Primary outcome
The primary outcome was the amount of pain associated
with subcutaneous injections of methotrexate.
Secondary outcomes
The secondary outcomes were the 1) predictors of injec-
tion-induced pain, 2) patient/family-reported side effects
associated with subcutaneous methotrexate, and 3) effect-
iveness of treatments for these side effects.
Data collection
1) Clinical Interview. A research assistant conducted a
standardized focused interview with the patient and
family members to ask about their experience with
subcutaneous administration of methotrexate. The
interview consisted of 18 questions which were
developed specifically for this study based on a
review of the literature. The interview required
approximately 10 minutes to complete.
2) Chart Review. Charts were reviewed to gather
information pertaining to medical diagnoses
and therapy.
3) Pain Measurements:
Participants were taught to how to use the FPS-R to
self-report pain, while caregivers were instructed in
the use of the FLACC scale to rate their children's
pain. One copy of each scale was provided for each
of the next two methotrexate injections to increase
the accuracy of the assessment. Participants then
returned the completed scales via mail or electronic
messaging to a single, secure address. An electronic
messaging reminder was sent four weeks after the
interview if the scales had not already been
submitted.
a/ Faces Pain Scale – Revised (FPS-R). This scale
consists of six gender-neutral faces depicting
“no pain” to “most pain possible”. The child is
instructed to point to the face that represents
how much pain he/she feels. Ordered faces are
scored 0-2-4-6-8-10. This instrument has
demonstrated validity and reliability in recording
Table 1 Demographic information of study participants
Mean age 11.2 years (SD = 3.9 years)
Mean duration of
Methotrexate therapy
2.5 years (SD = 2.1 years)
Sex Female: 28/41 68%
Rheumatologic diagnosis* JIA: 30/41 73%
Uveitis: 14/41 34%
Scleroderma: 10/41 24%
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4–17 [12,13].
b/ FLACC Behavioral Scale. This observational scale
comprises five items, namely, (F) Face; (L) Legs;
(A) Activity; (C) Cry; and (C) Consolability. Each
of these five behavioural categories is rated on a
scale 0 to 2 to provide an overall pain score
ranging from 0 to 10. This tool is valid and
reliable for children aged 4–18 [14,15].Dermato/Polymyositis: 2/41 5%
SLE 1/41 2%
Other 4/41 10%
Number of active joints
at time of interview
0 Active Joints: 34/41 82%
1 Active Joint: 5/41 12%
2 Active Joints: 1/41 2%








Other (i.e. topical): 8/41 20%
Folic acid 1 mg daily or 5 mg weekly 29/41 71%
None 12/41 29%
* Some participants had both JIA and uveitis.Statistical analysis
Descriptive statistics were used to analyze the demo-
graphics of the patient population and the frequency of
the outcomes of interest. The Intraclass Correlation
Coefficient was calculated to determine the level of con-
sistency between the FLACC score and Faces Pain Scale.
A Bland-Altman plot was also constructed to analyze
agreement between instruments. Simple and multiple lin-
ear regression were conducted to determine the asso-
ciation between both the FLACC score and Faces Pain
Scale and age, presence of side effects, and duration of
treatment. All analyses were conducted using SPSS v. 21
and R v. 3.0.2.
Ethics
This study was approved by the Children's Hospital of




Of the 42 patients who met the inclusion criteria for this
study, 41 consented to participate (participation rate
97.6%). The mean age was 11.2 years (SD = 3.9 yrs) and
68.3% of participants were female. Most of these patients
were diagnosed with JIA (73.2%; Table 1). Mean duration
of therapy with subcutaneous injections of methotrexate
was 2.5 years (SD = 2.1 years; Table 1). Throughout the
clinical interviews, the primary respondent was most
commonly the patient's mother (18/41, 43.9%), followed
by the patient herself/himself (13/41, 31.7%). Fathers
of the patients were the primary respondents in the re-
maining interviews (10/41, 24.4%). The majority of parti-
cipants (82.9%) had no active joints at the time of the
clinical interview. Use of subcutaneous methotrexate was
discontinued for 4 of the participants shortly after the
clinical interview as per the recommendation of their
rheumatologist. Two of these patients were advised to dis-
continue subcutaneous methotrexate because of sustained
remission. The other two participants were unable to toler-
ate the subcutaneous therapy and were therefore switched
to oral methotrexate. These children identified their dislike
of the injections as their main reason for refusing the sub-
cutaneous therapy. Therefore, 37 patients were trained onthe use of the pain scales to rate the amount of pain with
future injections. Twenty-nine of the 37 participants
returned the completed pain scales (response rate 78.4%).
The majority of patients (92.7%) reported excellent adher-
ence to the treatment regimen, missing less than one dose
per month.
Subcutaneous Methotrexate injection techniques and
setting
All but one of the patients used methotrexate 25 mg/ml
solution for injection in 1 cc or 3 cc syringes with 30
gauge ½” needles. One patient used Metoject® 20 mg/
2 ml prefilled syringes. The majority of participants re-
ceived methotrexate injections in the evening (30/41,
73.2%). Weekend days were the most popular for injec-
tion administration (31/41, 75.6%). In most families, the
child's mother was responsible for administering the
injection (24/41, 58.5%), followed by the father (10/41,
24.4%). Only 12.2% of patients regularly injected the
medication themselves. The upper arm was the pre-
ferred site of injection in 70.7% of patients. Approxi-
mately 19.5% of caregivers reported preparing their
children for the injection by "counting to three" in ad-
vance; the remaining participants did not receive warning
before needle insertion.
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Methotrexate
The set of pain scores from the first injection was used
in statistical analyses. Of the 29 patients who completed
the pain scales, the median amount of self-reported pain
on the FPS-R was 2/10; 18 (62.1%) patients reported nil
to mild pain (FPS-R score 0–2), and 9 (31.0%) reported
moderate pain (FPS-R score 4–6). Two participants re-
ported severe pain (FPS-R 8–10; Figure 1). The patient
who reported the highest amount of pain was the only
one using Metoject® 20 mg/2 ml prefilled syringes and
was excluded from further analyses.
Similarly, analysis of observational pain scores from
the FLACC resulted in a median score of 1/10. The ma-
jority of caregivers (20/29; 68.9%) rated the pain 3/10 or
less (Figure 1). Pain scores from the FLACC and FPS-R
showed good overall agreement (ICC = 0.87, 95% CI:
0.75-0.94).
Predictors and alleviators of pain
Associations between the amount of self-reported pain
on the FPS-R and presence of side effects, duration of
therapy, and patient age were tested. In univariate testing,
higher intensity of pain was associated with presence of
side effects (p = 0.004; Figure 2), but not duration of
therapy (p = 0.20) or age (p = 0.24). Results were largely
unchanged in multiple linear regression adjusting for all
three variables. The presence of side effects was independ-
ently associated with a 2.6 unit higher FPS-R (95% CI: 1.0-
4.1; p < 0.01). Neither age (0.1 units lower FPS-R per year,
95% CI: 0.4 units lower to 0.1 higher; p = 0.24) nor dur-
ation of therapy (0.02 units higher FPS per month, 95%
CI: −0.004- 0.05; p = 0.10) were found to be independently
associated with FPS-R.
Similar results were found when presence of side effects,
duration of therapy, and patient age were tested for associ-
ation with the amount of pain reported using the FLACC.
Univariate analyses demonstrated that higher intensity ofFigure 1 Amount of self-reported or observational pain as
measured on the FPS-R and FLACC.pain was associated with the presence of side effects
(p = 0.03), but not with duration of therapy (p = 0.45)
or age (p = 0.33). Multiple linear regression adjusting
for all three variables demonstrated that the presence
of side effects was independently associated with a 2.1 unit
higher FLACC (95% CI: 0.2-4.0, p = 0.03). Age (−0.10 units
lower per year, 95% CI: −0.36-0.16; p = 0.45) and duration
of therapy (0.01 units higher per month, 95% CI: −0.02-
0.05; p = 0.36) were not significantly associated with
FLACC scores.
Participants were asked if they made past or current
attempts to reduce the pain associated with the injections
through any combination of various pharmacological
and psychological techniques. The majority of participants
(80.5%) tried at least one method. The frequency of use
and reported efficacies of these methods are described in
Table 2.
Participants were asked to describe changes in pain
intensity of methotrexate injections over the course of
therapy. While 7/41 patients (17.1%) reported that the
pain has worsened over time, 12/41 patients (29.3%) repor-
ted decreased intensity. An additional 19/41 (46.3%) of
patients reported no change in pain intensity throughout
the course of therapy, and 3/41 (7.3%) of participants were
unable to identify any consistent trend.
Subjective side effects
Most participants (25/41, 61.0%) experienced at least
one clinical adverse effect (Figure 3). The two most com-
monly reported side effects were nausea and vomiting
(56.1% and 34.1% of patients, respectively). Less frequently
reported side effects included fatigue (29.2%), anorexia
(26.8%), headache (14.6%), and recurrent oral ulcers (9.8%).
Of patients who experienced nausea, 52.2% used dimen-
hydrinate while 26.1% used ondansetron to manage their
symptoms. Similarly, many patients who experienced
vomiting tried to alleviate their symptoms with di-
menhydrinate (57.1%) or ondansetron (28.5%). While di-
menhydrinate effectively treated nausea in only 41.7% of
patients, most patients reported good efficacy of ondanse-
tron (83.3%). A similar effect was observed for treatment
of vomiting (efficacy of dimenhydrinate 12.5% versus
ondansetron 75.0%). None of the patients used ginger to
alleviate nausea/vomiting.
The timing of onset and the duration of clinical adverse
effects were also recorded (Table 3). Anticipatory nausea
was experienced by 56.5% of all participants who reported
this symptom; the remainder felt nauseous after the injec-
tions. Similarly, 42.9% of all reported vomiting was anti-
cipatory. Most reported subjective adverse effects were
relatively short-lived. Except for oral ulcers, clinical side
effects resolved within 24 hours in 92.7% of patients.
Of 19 patients who had used oral methotrexate in the
past, only 26.3% felt that the oral form was better tolerated.
Figure 2 Gastrointestinal side effects and methotrexate injection pain. The presence of nausea or vomiting from methotrexate is associated
with higher injection pain scores on both the FPS-R and FLACC.
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route (6/19, 31.6%), had no preference (7/19, 36.8%), or
were undecided (1/19, 5.3%).
Discussion
Subcutaneous injections of methotrexate are associated
with a small amount of pain
The participants within our study reported mild pain
associated with the weekly subcutaneous methotrexate
injections (2/10 on the FPS-R). Interestingly, approximately
a third of patients and a third of caregivers reported no
injection pain (FPS-R or FLACC score of 0). Compared to
other studies that have used the FPS-R to measure pain
associated with analogous procedures, our participants re-
ported a relatively low amount of pain. For example,
Berberich and Landman [16] measured pain associated
with intramuscular and subcutaneous immunizations in
children aged 4 to 6 using the FPS-R and FLACC. With-
out intervention, the pain was rated as 8.00 and 7.00
using the FPS-R and FLACC, respectively. Studies investi-
gating the amount of pain associated with venipuncture in
children typically report a median FPS-R score of 4.00 to
7.00 if no prophylactic intervention is applied [17-19].
While differences between study populations may partially
account for this higher level of pain, our findings suggest
subcutaneous methotrexate injections produce less painTable 2 Techniques to alleviate pain associated with subcuta
Method Examples Participan
Ice Before and/or after injection 14 (34.1%)
Comfort Positions Hugging, holding hands 21 (51.2%)
Rewards Food treats, toys, fun activities 20 (48.8%)
Reassurance “It will be fast”, “Don’t worry” 22 (53.6%)
Distraction Music, TV, video games 21 (51.2%)
Medicinal Advil, Tylenol, EMLA, anesthetic spray 9 (22.0%)than venipuncture. Another study found that children
aged 5 to 12 reported an average pain score of 2.63 on the
FPS-R following ear piercing, which is similar to the re-
ported amount of methotrexate injection-associated pain
[20]. These comparisons may be useful when counseling
parents and children about subcutaneous methotrexate
therapy.
Though the median amount of pain reported in our
study is relatively low, it is important to note that some
children experienced moderate to severe pain with the
injections. For example, two of the participants recruited
for this study refused to regularly receive the injections
due to the associated discomfort. Within our study, 92.7%
of participants reported missing less than one dose of
methotrexate per month. The rate of reported paediatric
adherence to methotrexate therapy (either oral or subcu-
taneous) within the existing literature is difficult to assess
due to various operational definitions for adherence. How-
ever, adherence seems to vary from 82% to 95.9% be-
tween studies [11,21]. The real adherence rate in our
population may have been much lower than what we
have captured through self-report data. It is important
for clinicians to understand the challenges some pa-
tients face and to be prepared to discuss techniques for
pain control in order to optimize adherence and treatment
efficacy.neous injections of methotrexate







Figure 3 Self-reported frequency of clinical adverse effects
associated with weekly subcutaneous injections of methotrexate.
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available methods of pain control
Families who participated in this study reported using a
variety of techniques to alleviate the pain associated with
injections. Interestingly, two thirds of our patients who
tried ice to cool the skin prior to or immediately after
injection found this intervention effective despite a sys-
tematic review of physical techniques to reduce injection
pain that found inconsistent evidence to support the
benefit from ice application [22] and subsequent clinical
guidelines for administration of vaccines that found
insufficient evidence to recommend the use of ice to
reduce injection pain [23]. Further studies are neededTable 3 Adverse effects related to subcutaneous injections of
Adverse effect Prevalence Onset in relation to injection
Nausea 23 (56%) Before
During/After (< 1 hour)
After (1–6 hours)
After (> 6 hours)
Vomiting 14 (34%) Before
During/After (< 1 hour)
After (1–6 hours)
After (> 6 hours)
Headache 6 (15%) < 12 hours
12 - 24 hours
> 24 hours
Fatigue 12 (29%)
Anorexia 11 (31%)on the application of ice for methotrexate injection
pain.
Approximately half of our participants reported using
comfort positions, such as hugging or hand-holding, to
reduce to the injection pain. Two thirds of these patients
reported experiencing some degree of pain relief. This is
in keeping with prior research reports showing benefits
of hugging children during painful procedures [24,25].
In addition, studies with infants suggest skin-to-skin con-
tact and sitting upright as opposed to supine decrease
injection-associated pain [22].
Another common technique our families used to reduce
pain involved providing rewards, either in the form of
food treats (including sweets), toys, or enjoyable activities.
Most of our patients reported experiencing pain relief due
to the promise of reward. While there is no comparative
study on the effects of promised future rewards on pain, a
recent Cochrane review of randomized control studies
investigating the use of oral glucose or sucrose for pain
relief during needle-related procedures found these tech-
niques did not reduce pain scores in school-aged children
[26]. This discrepancy may relate to the self-report nature
of our study. For example, the respondents might have
said the rewards were helpful because they enjoyed receiv-
ing them, even if they did little to relieve pain during the
injection itself.
Systematic reviews have reported that distraction is
an effective coping method used to alleviate paediatric
needle-related pain [27-29]. As expected, about half of our
patients reported experiencing pain relief with distraction.
There are many different types of distraction; this categorymethotrexate
Number (%) Duration Number (%)
13 (56%) 0 - 5.9 hours 9 (39%)
6 (26%) 6 - 11.9 hours 4 (17%)
2 (9%) 12 - 23.9 hours 9 (39%)
5 (22%) ≥ 24 hours 1 (4%)
6 (43%) 0 - 5.9 hours 12 (86%)
4 (29%) 6 - 11.9 hours 0 (0%)
3 (21%) 12 - 23.9 hours 1 (7%)
3 (21%) ≥ 24 hours 1 (7%)
3 (50%) < 12 hours 5 (83%)
2 (33%) 12 - 24 hours 1 (17%)
1 (17%) > 24 hours 0 (0%)
< 12 hours 1 (8%)
12 - 24 hours 9 (75%)
> 24 hours 2 (17%)
< 12 hours 4 (36%)
12 - 24 hours 6 (54%)
> 24 hours 1 (9%)
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tion (parent, child, or health care provider) or the object
used to provide distraction itself (bubbles, toys, passive
electronics such as television, active electronics such as
video games). The efficacy of distraction for pain relief
may vary amongst these domains. For example, there is
some evidence that child-led or nurse-led distraction de-
creases pain on more metrics than parent-led distraction
[27]. Furthermore, prior studies suggest the efficacy of
distraction techniques for pain control depend upon the
particular method used and the temperament of the
child [29-31]. Our findings are consistent with existing
literature suggesting distraction may be an effective me-
thod of pain relief.
Controlling methotrexate induced nausea and vomiting
may alleviate injection pain
We found that experiencing nausea or vomiting in asso-
ciation with the methotrexate injections was associated
with higher pain scores on the FPS-R and FLACC. These
gastrointestinal symptoms are the most common side ef-
fects associated with methotrexate therapy and have been
linked to a reduced health-related quality of life [11]. It is
possible that the distress caused by the anticipation of
these side effects heightens anxiety and pain perception.
Given this association, adequate control of these symp-
toms is desirable for alleviating injection-associated pain
and its long-term consequences. Results of our study sug-
gest that dimenhydrinate has only a very limited role in
treatment of methotrexate associated nausea and vomit-
ing, and perhaps ondansetron should be the treatment
of choice in this situation. There is some evidence that
psychological intervention may be beneficial to managing
anticipatory nausea and vomiting when methotrexate is
prescribed for JIA [32].
Study limitations
Due to the observational nature and relatively small size
of our study, we are unable to strongly recommend for or
against particular methods of pain relief. However, each of
the techniques described above provided relief for at least
some participants. The low cost and low risk of these
interventions justifies their trial. The small size of our
study also prevented stratification of participants by age,
rheumatologic condition, and anxiety. Further research is
needed to determine whether the results generalize to dif-
ferent populations within these categories.
Conclusions
This study provides detailed information on the amount
of patient-perceived pain with subcutaneous injections
of methotrexate and potential pain aggravating factors.
In addition, the paper explores patients' and caregivers'
perception of methotrexate-associated side effects andtheir coping strategies. We hope the results will help
clinicians counsel patients and families starting weekly
methotrexate injections. The possible association between
the presence of gastrointestinal side effects and higher
reported amounts of pain warrants further study. Careful
management of these adverse effects may help to avoid
the negative long-term consequences of inadequately ma-
naged procedural pain.
Consent
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